Complexity made simple in diffuse large B-cell lymphoma.

Aster, Jon; Kutok, Jeffery · Clin Cancer Res · 2009

editorial · Level V

Where this comes from

Abstract

Diffuse large B cell lymphoma (DLBCL) is a heterogeneous disease and response to therapy is difficult to predict. An algorithm to sort DLBCL cases using a series of five immunohistochemical markers (GCET1, CD10, BCL6, MUM1, FOXP1) accurately predicts survival in patients treated with current chemotherapeutic regimens.

Medical subject headings